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Background  and objectives:  Serum  Hepatitis  B surface  Antigen  (HBsAg)  levels  correlate  with  hepatitis  B
virus intrahepatic  covalently  closed  circular  DNA  and  may  predict  response  to treatment.  Currently,  2
commercial  platforms  are  available  for HBsAg  quantiﬁcation  in clinical  practice,  the  Architect  HBsAg  QT
and the  Elecsys  HBsAg.  We  aimed  to  directly  compare  the results  of  these  assays.
Study  design:  HBsAg  levels  were  measured  in  1427  serum  samples  from  HBeAg-positive  chronic  hepatitis
B  patients  who  participated  in a  randomized  trial of peginterferon  alfa-2b  ± lamivudine.  Samples  were
extracted  from  our  serum  bank,  thawed,  and  subsequently  analysed  for  HBsAg  levels  using  both  assays.
Results:  Of  1427  samples,  242 (17%)  were  taken  before  and  1185  during  the  treatment  phase  of  the study.
Distribution  of  HBV  genotypes  was  447  (31%)  genotype  A, 125  (9%)  B, 210  (15%)  C  and  534 (37%)  D.
Correlation  between  Architect  and  Elecsys  results  was  high  (r =  0.96,  p  < 0.001).  By  Bland–Altman  anal-
ysis,  agreement  between  the  two assays  was  close  (mean  difference  between  Architect  and  Elecsys:
−0.01  log  IU/mL,  95% CI: −0.55–0.52  log IU/mL),  also when  analysed  separately  for HBV  genotypes  A–D.
Additionally,  the  performance  of  our  recently  published  stopping  rule  for HBeAg-positive  patients  treated
with peginterferon  was  comparable:  the  negative  predictive  values  were  96%  and  98% for  Elecsys  and
Architect,  respectively.
Conclusions:  There  is a high  correlation  and close  agreement  between  quantitative  HBsAg  measure-
ments  conducted  with  the  Architect  and  the Elecsys.  Clinical  prediction  rules  derived  from  data  from
one platform  can  be applied  on the  other;  both  can therefore  be used  in clinical  practice.. Background and objectives
Chronic hepatitis B (CHB) is an important global health problem,
ith over 350 million people being chronically infected.1 Hepati-
is B surface Antigen (HBsAg) is an established marker of infection
ith the hepatitis B virus (HBV), and is therefore often used as screening tool.1 In addition to its use as a qualitative marker,
ecent innovations have allowed for the quantitative assessment
f HBsAg in serum. The clinical relevance of HBsAg levels is derived
Abbreviations: CHB, chronic hepatitis B; HBsAg, Hepatitis B surface Antigen;
BV, hepatitis B virus; cccDNA, covalently closed circular DNA; PEG-IFN, peginter-
eron; HBeAg, hepatitis B e antigen.
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from its correlation with intrahepatic HBV covalently closed cir-
cular (ccc) DNA, the main replicative template of HBV.2,3 Through
this association, serum HBsAg is hypothesized to be a marker for
immunological response to therapy, independent of virological
response as measured using HBV DNA levels.
Several clinical applications of HBsAg levels have been
described. For example, HBsAg levels appear to differentiate
patients in the inactive carrier state (persistent HBeAg negativity,
with HBV DNA <2000 IU/mL, normal ALT4) from those with active
disease or from inactive carriers with a high probability of sub-
sequent relapse.5–7 Furthermore, recent studies have shown that
on-treatment HBsAg levels are predictive of a durable off-treatment
response to peginterferon (PEG-IFN), and can accurately identify
non-responders early during therapy, both in HBeAg-positive,8–10
Open access under the Elsevier OA license.and HBeAg-negative11,12 patients.
Currently, multiple diagnostic assays are available for quantiﬁ-
cation of HBsAg. The most widely used is the Architect assay,13
but HBsAg quantiﬁcation may  also be performed using the Elecsys
1  Clinical Virology 51 (2011) 175– 178
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Fig. 1. Correlation between HBsAg measurements using the Architect HBsAg QT
between the two test results was  <1 log IU/mL.76 M.J. Sonneveld et al. / Journal of
latform (HBsAg Quant Package Insert, Roche Diagnostics 2011).
he comparability of the two assays in measuring HBsAg lev-
ls in patient sera is however unknown. The aim of our study
as therefore to compare quantitative HBsAg measurements con-
ucted with the Architect HBsAg QT assay with measurements
onducted with the Elecsys HBsAg in a large number of patient
amples.
. Study design
.1. Assays
HBsAg was quantiﬁed using the Architect platform (Abbott
aboratories, Abbott Park, IL, USA) and Elecsys HBsAg (Roche
iagnostics, Indianapolis, IN, USA). HBsAg testing was  performed
ccording to the manufacturer’s package insert and with test kits
rom a single lot. For the Architect, sample material and anti-
Bs-coated paramagnetic microparticles are combined. After a
ashing step, acridinium labelled anti-HBs conjugate is added, and
fter another washing cycle, pre-trigger and trigger solutions are
dded. The subsequent chemiluminescent reaction is measured
n relative light units, which can be converted directly to HBsAg
nits. The range of the assay is 0.05–250 IU/mL, and if results
ere outside of this range, material was diluted according to the
anufacturer’s recommendations (package insert HBsAg, Abbott
aboratories 2008). The Elecsys HBsAg assay is an immunoassay
hat measures HBsAg using a sandwich principle: ﬁrst a com-
lex is formed with two monoclonal HBsAg-speciﬁc antibodies,
ne of which is biotinylated, the other labelled with a ruthenium
omplex. After addition of streptavidin-coated microparticles, the
omplexes bind to the solid phase through interaction of bio-
yn and streptavidin. The mixture is subsequently aspirated into
 measuring cell, where application of a voltage then induces
hemiluminescent emission, which is measured by a photomul-
iplier. The measured results are compared to a cut-off value
btained through HBsAg calibration. The obtained signal to
ut-off index may  then be converted to IU/mL using a WHO
tandard conversion factor of 0.055 IU/mL (all methodology as
er Elecsys package inserts for quantitative HBsAg measure-
ent, Roche Diagnostics 2011). All assays were performed at
he Erasmus MC  University Medical Center in Rotterdam, the
etherlands.
.2. Samples
Samples for this study were derived form a multicenter ran-
omized trial investigating the efﬁcacy of 52 weeks of PEG-IFN
lfa-2b ± lamivudine for the treatment of HBeAg-positive CHB.14
n- and exclusion criteria for this study have been previously
ublished.14 Samples were stored after the study in a large
erum bank. For this study, samples were thawed and serum was
xtracted for quantitative HBsAg measurements using the two
ssays. HBV genotype was assessed using the INNO-LiPA line-probe
ssay.15
.3. Statistical analysis
After transformation to log(10) IU/mL, the results of the
wo assays were compared using correlation (Pearson) and
land–Altman analyses. A p value of <0.05 was considered statisti-
ally signiﬁcant. Additionally, the results of a previously reported
topping rule for PEG-IFN therapy, established using the Architect
ssay,10 were applied on the Elecsys data for comparison.assay and the Elecsys HBsAg.
3. Results
3.1. Samples
A total of 1427 samples were measured using both assays, of
which 242 (17%) were samples taken before treatment and 1185
(83%) were taken during the treatment phase. The samples retested
for this study represent a random subset of the original study
population.10
3.2. Comparison between Architect and Elecsys measurements
A correlation of measurements conducted with the two  assays
is shown in Fig. 1; correlation between the assays was excellent
(r = 0.96, p < 0.001). Using regression analysis, it was determined
that HBsAgArchitect = 0.979 * (HBsAgElecsys) + 0.074. Bland–Altman
analysis (depicted in Fig. 2) revealed a close agreement between
the two tests: the results of the Elecsys were on average only
0.01 log IU/mL higher than the Architect assay. Overall, the range
for the mean difference between the two test results (±2 stan-
dard deviations) was −0.55 through 0.52 log IU/mL. Additionally, in
83.4% of paired samples the difference between the two assays was
<0.25 log IU/mL, in 93.6% <0.5 log IU/mL and in 98.2% the differenceFig. 2. Bland–Altman plot of HBsAg measurements using the Architect HBsAg QT
assay and the Elecsys HBsAg. Dashed lines represent 95% conﬁdence limits.
M.J. Sonneveld et al. / Journal of Clinic
Table 1
Bland–Altman analysis per genotype.
Genotype Bias 95% limits of agreement
−2SD +2SD
A (n = 447) −0.051 −0.555 0.454
B  (n = 125) 0.063 −0.414 0.540
C  (n = 210) −0.053 −0.387 0.281
D  (n = 534) 0.011 −0.610 0.631
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pverview of the results of the Bland–Altman comparison of the Architect versus the
lecsys HBsAg data in samples from patients with HBV genotypes A, B, C and D. SD,
tandard deviation.
.3. Comparison according to HBV genotype
Of the 1427 samples, 447 (31%) were taken from patients with
BV genotype A, 125 (9%) from patients with genotype B, and 210
15%) and 534 (37%) from patients with genotypes C and D, respec-
ively. The remaining samples (n = 111, 8%) were from patients who
arboured different or mixed HBV genotypes, and were not consid-
red for this part of the analysis. The results of the two  assays were
omparable, within narrow conﬁdence limits, irrespective of HBV
enotype (Table 1).
.4. Retesting of samples with high divergence
A divergence of ≥1 log IU/mL was found in 25 samples (1.8%).
igh divergence was not related to HBV genotype or treatment
eek. Sufﬁcient serum for retesting on both platforms was  avail-
ble in 20 (80%). The test results observed in the retested samples
ere highly correlated (0.99, p ≤ 0.001), and the mean difference
etween the results for the Architect when compared to the Elec-
ys was −0.10 log IU/mL, with none of the samples with detected
BsAg diverting ≥0.5 log IU/mL. The mean differences between ﬁrst
nd second measurement were −0.02 log IU/mL for the Architect
nd 0.02 log IU/mL for the Elecsys.
.5. Comparison of the performance of a threshold based
topping-rule
Recently, we have reported a stopping-rule for HBeAg-positive
atients treated with PEG-IFN, based on the presence or absence
f a decline in serum HBsAg levels from baseline. Patients
ithout a decline from baseline to week 12 of treatment
log(HBsAgweek12) − log(HBsAgbaseline) ≥ 0) had a very low proba-
ility of response (<5%), and we advised to discontinue therapy in
hese patients.10 For the current study, we applied this threshold
ased rule on the subset of patients that had both Architect and
lecsys data available. For this analysis, a representative subset of
81 patients of the original study (out of 221, 82%) were included. As
hown in Table 2, the stopping rule performed very well within the
ubset of patients included in this analysis, and the positive predic-
ive values (PPVs) and negative predictive values (NPVs) obtained
ith the two assays were very similar (NPVs: 96% for the Elecsys,
ompared to 98% for the Architect).
able 2
ositive and negative predictive values of the stopping-rule.
Response
Architect Elecsys
No Yes PPV NPV No Yes PPV NPV
Any decline week 12
Yes 97 30 24% – 101 29 22% –
No  53 1 – 98% 49 2 – 96%
esponse was  deﬁned as HBeAg loss and HBV DNA < 10,000 copies/mL 6 months
fter discontinuation of treatment. NPV, negative predictive value; PPV, positive
redictive value.al Virology 51 (2011) 175– 178 177
4. Discussion
This is the ﬁrst large study comparing the two  major com-
mercial platforms, Architect and Elecsys, for HBsAg quantiﬁcation
in patient sera. We  found a very close agreement between the
assays, irrespective of HBV genotype. Both assays can therefore be
used for HBsAg quantiﬁcation in clinical practice in HBeAg-positive
patients.
Presence of HBsAg is commonly used as a screening tool
for infection with HBV, and is often detectable in serum before
evidence of liver inﬂammation is present.16 However, recent tech-
nological advancements have allowed for the quantiﬁcation of
HBsAg in serum. The clinical relevance of these HBsAg levels is
derived from the apparent correlation with intrahepatic cccDNA
levels, which are strong predictors of sustained response to treat-
ment, but can only be assessed invasively through a liver biopsy.3,17
Recent studies have shown that HBsAg levels may  be used in the
monitoring of HBV therapy. During therapy with nucleos(t)ide ana-
logues (NA), HBV DNA is potently suppressed to undetectable levels
in a majority of patients after 48 weeks of treatment, but only mod-
erate declines in HBsAg levels are achieved.8,11,18 HBsAg and HBV
DNA therefore seem largely uncorrelated during antiviral therapy,
and HBsAg decline may  signify an immunological response that is
independent of HBV DNA suppression as achieved with NA based
treatment. Monitoring of HBsAg levels during antiviral therapy for
CHB may  therefore provide additional information when compared
to HBV DNA levels alone. One year of PEG-IFN therapy induces
a pronounced decline in HBsAg levels, especially in patients who
achieve an off-treatment sustained response.8,11,12,19,20 The differ-
ences in HBsAg decline between responders and non-responders
can be used to predict success of therapy.10,12,20 Additionally,
HBsAg decline during therapy with NA may  be used to predict
subsequent loss of HBsAg through prolonged follow-up.21,22
Most of the recent studies on HBsAg quantiﬁcation were con-
ducted using the Architect platform, but the manual for HBsAg
quantiﬁcation on the Elecsys was  recently released (HBsAg Quant,
Roche Diagnostics 2011). The comparability of the results of the two
assays was however still unknown, and the limited insight into the
agreement between the two  assays prohibited extrapolation of data
and ﬁndings from studies using either platform to studies or clin-
ics that use the other. The current study was designed to address
these issues, and we  have now shown that the two  assays provide
comparable results. Importantly, there is a very close agreement
between the two platforms, within ±0.5 log IU/mL in 94% of the
samples that were tested, and this close agreement is independent
of HBV genotype.
In addition to the use of HBsAg in monitoring therapy efﬁcacy,
several reports have now provided stopping-rules for PEG-IFN ther-
apy for CHB. A post hoc analysis of the phase 3 study of PEG-IFN
alfa-2a showed that lower HBsAg levels during treatment were
associated with a sustained off-treatment response.8 Similarly, we
showed that HBeAg-positive patients without a decline at week
12 of therapy had a low probability of sustained response, and no
chance of HBsAg loss, even through long term follow-up.10 The
current study shows that our ﬁndings reported from data gath-
ered using the Architect can be extrapolated to measurements
conducted with the Elecsys. This implies that published threshold
or decline based prediction rules established using either plat-
form may  be used on the other as well, without losing predictive
accuracy. Furthermore, our ﬁndings can also be extended to mea-
surements conducted with other Cobas serology systems, which
share characteristics with the Elecsys. This should make quantita-
tive HBsAg diagnostics more easily accessible around the globe.
In summary, the current study shows a high correlation and
agreement between quantitative HBsAg measurement conducted
with the Architect and Elecsys assays, irrespective of HBV geno-
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